Volume 105, Issue 1 p. 49-56

Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK

Richard Olivier Fourcade

Richard Olivier Fourcade

Service d’Urologie Centre Hospitalier Auxerre, France, *United BioSource Corporation, London, UK, Global Health Outcomes, GSK, Research Triangle Park, NC, USA, United BioSource Corporation, Montréal, Québec, Canada, § Department of Urology, Hospital Clínic, Barcelona, Spain, and Urology Center of Excellence Research and Development Centre, Glaxo SmithKline, Madrid, Spain, and Research Triangle Park, NC, USA

Search for more papers by this author
Ágnes Benedict

Corresponding Author

Ágnes Benedict

Service d’Urologie Centre Hospitalier Auxerre, France, *United BioSource Corporation, London, UK, Global Health Outcomes, GSK, Research Triangle Park, NC, USA, United BioSource Corporation, Montréal, Québec, Canada, § Department of Urology, Hospital Clínic, Barcelona, Spain, and Urology Center of Excellence Research and Development Centre, Glaxo SmithKline, Madrid, Spain, and Research Triangle Park, NC, USA

Ágnes Benedict, Health Care Analytics Group, Europe, United BioSource, 20 Bloomsbury Square, London WC1A 2NS, UK.
e-mail: [email protected]Search for more papers by this author
Libby K. Black

Libby K. Black

Service d’Urologie Centre Hospitalier Auxerre, France, *United BioSource Corporation, London, UK, Global Health Outcomes, GSK, Research Triangle Park, NC, USA, United BioSource Corporation, Montréal, Québec, Canada, § Department of Urology, Hospital Clínic, Barcelona, Spain, and Urology Center of Excellence Research and Development Centre, Glaxo SmithKline, Madrid, Spain, and Research Triangle Park, NC, USA

Search for more papers by this author
Michael E. Stokes

Michael E. Stokes

Service d’Urologie Centre Hospitalier Auxerre, France, *United BioSource Corporation, London, UK, Global Health Outcomes, GSK, Research Triangle Park, NC, USA, United BioSource Corporation, Montréal, Québec, Canada, § Department of Urology, Hospital Clínic, Barcelona, Spain, and Urology Center of Excellence Research and Development Centre, Glaxo SmithKline, Madrid, Spain, and Research Triangle Park, NC, USA

Search for more papers by this author
Antonio Alcaraz

Antonio Alcaraz

Service d’Urologie Centre Hospitalier Auxerre, France, *United BioSource Corporation, London, UK, Global Health Outcomes, GSK, Research Triangle Park, NC, USA, United BioSource Corporation, Montréal, Québec, Canada, § Department of Urology, Hospital Clínic, Barcelona, Spain, and Urology Center of Excellence Research and Development Centre, Glaxo SmithKline, Madrid, Spain, and Research Triangle Park, NC, USA

Search for more papers by this author
Ramiro Castro

Ramiro Castro

Service d’Urologie Centre Hospitalier Auxerre, France, *United BioSource Corporation, London, UK, Global Health Outcomes, GSK, Research Triangle Park, NC, USA, United BioSource Corporation, Montréal, Québec, Canada, § Department of Urology, Hospital Clínic, Barcelona, Spain, and Urology Center of Excellence Research and Development Centre, Glaxo SmithKline, Madrid, Spain, and Research Triangle Park, NC, USA

Search for more papers by this author
First published: 16 December 2009
Citations: 44

Abstract

Study Type – Economic (prospective cohort)
Level of Evidence 2a

OBJECTIVE

To calculate the total cost per patient of prostate cancer treatment and the economic cost burden by stage, in the first year after diagnosis, for five European countries.

METHODS

Data from the Information Management Systems, Inc. database, survival data, expert opinion, published data and unit costs from various published official sources were used to calculate total costs per patient by stage for each country, from a payer’s perspective. Diagnostic costs, first surgery, radio-, chemo- and hormonal therapy costs were included. Costs were aggregated for incident cases.

RESULTS

The mean direct costs per patient for initial treatment were €3698 in Germany, €3256 in Spain, €3682 in the UK, €5226 in Italy and €5851 in France. The total costs for all diagnosed patients in the first year from diagnosis were (million €) 116.7 (UK), 244 (Germany), 385 (France), 202 (Italy) and 114.6 (Spain).

CONCLUSIONS

The direct initial healthcare cost burden of the most common non-skin-related male cancer, prostate cancer, in France, Germany, Italy, Spain and the UK is considerable. Given the high and increasing prevalence of prostate cancer due to ageing populations in Europe, and the significant cost burden of the disease, national health policy makers should be aware of prostate cancer as a priority disease area.